BioMarin Pharmaceutical has struck a deal to purchase fellow biotechnology firm Amicus Therapeutics for about $4.8 billion in money.
Source link
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
Related Posts
SpaceX stock sinks 2%, continuing to cool after three-day rally
SpaceX shares dropped 2% on Thursday, because the inventory’s current rally confirmed indicators of cooling following a record-breaking IPO final…
TikTok signs agreement to create new U.S. joint venture, memo says
Samuel Boivin | Nurphoto | Getty Photographs TikTok CEO Shou Zi Chew advised staff on Thursday that the corporate’s U.S.…
Bose QuietComfort Ultra Earbuds (2nd Gen): Excellent Buds
When it comes to cutting out annoying outside noise, there is no brand in history that has denatured more decibels…